H

Horizon Therapeutics PLC
F:HPR

Watchlist Manager
Horizon Therapeutics PLC
F:HPR
Watchlist
Price: 110.2 EUR Market Closed
Market Cap: 25.3B EUR

Relative Value

There is not enough data to reliably calculate the relative value of HPR.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HPR Relative Value
Base Case
Not Available
H
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
7.5
Median 5Y
7.5
Industry
7.9
vs History
vs Industry
Median 3Y
62.3
Median 5Y
60.2
Industry
23.7
vs History
vs Industry
Median 3Y
26.2
Median 5Y
26.2
Industry
22
vs History
vs Industry
Median 3Y
33.8
Median 5Y
32.5
Industry
23.8
vs History
vs Industry
Median 3Y
5.1
Median 5Y
5.1
Industry
3.3
vs History
vs Industry
Median 3Y
7.5
Median 5Y
7.5
Industry
8.3
vs History
vs Industry
Median 3Y
10
Median 5Y
10
Industry
10.1
vs History
vs Industry
Median 3Y
28.6
Median 5Y
28.4
Industry
6.4
vs History
vs Industry
Median 3Y
48.2
Median 5Y
47.9
Industry
7
vs History
vs Industry
Median 3Y
26.2
Median 5Y
26.3
Industry
8.3
vs History
vs Industry
Median 3Y
28.5
Median 5Y
28.6
Industry
6.5
vs History
vs Industry
Median 3Y
4.1
Median 5Y
3.9
Industry
5.7

Multiples Across Competitors

HPR Competitors Multiples
Horizon Therapeutics PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Horizon Therapeutics PLC
F:HPR
25.2B EUR 8.1 67.6 31 52.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 798 004.3 -160 636.9 -195 064.4 -192 838.5
US
Abbvie Inc
NYSE:ABBV
394.7B USD 6.6 168.1 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
170.9B USD 4.8 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
149.5B USD 5.1 18.4 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.4 -531.9 -579.2 -563.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.7 13.2 16.5
NL
argenx SE
XBRU:ARGX
45.9B EUR 15 35.2 60.9 62.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 202.7 158 191.6
P/E Multiple
Earnings Growth PEG
IE
H
Horizon Therapeutics PLC
F:HPR
Average P/E: 176
67.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 636.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
AU
CSL Ltd
ASX:CSL
19.7
11%
1.8
NL
argenx SE
XBRU:ARGX
35.2
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 202.7
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
H
Horizon Therapeutics PLC
F:HPR
Average EV/EBITDA: 38.7
31
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 064.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
13.2
8%
1.7
NL
argenx SE
XBRU:ARGX
60.9
839%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
H
Horizon Therapeutics PLC
F:HPR
Average EV/EBIT: 46.5
52.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 838.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.5
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A